HEPION PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
HEPION PHARMACEUTICALS, INC. (HEPA) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 6.02 thousand shares for the 12-month period ending 2017-06-30, per its 10-K filed 2019-03-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2019-03-14
- HEPION PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 6.02K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month as first filed |
|---|---|---|
| 2017-06-30 | 6.02K shares 10-K · filed 2019-03-14 | 48.19K shares 10-K · filed 2017-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |